Mission Statement, Vision, & Core Values (2026) of Inner Mongolia Furui Medical Science Co., Ltd.

From its roots in Ulanqab to a Beijing headquarters and a global footprint spanning subsidiaries in France, the United States, Germany, Spain, the United Kingdom, Italy, Singapore and Hong Kong, Inner Mongolia Furui Medical Science Co., Ltd. has built a focused healthcare empire dedicated to liver disease prevention and treatment-established in 1998 and publicly listed on ChiNext in 2010 under ticker 300049-that combines managed-care programs targeting high‑risk liver cancer populations, standardized secondary prevention therapies, and outcome‑based payment models tied to treatment effectiveness; driven by a mission to "Keep every family away from liver cancer", a vision of becoming a respectful manufacturer and service provider with industry reputation, and core values of integrity, innovation, customer focus, collaboration, responsibility and executional efficiency, Furui's portfolio includes the medical device subsidiary Echosens (founded in 2001) and its non-invasive FibroScan® technology, aligning operational strategy with China's Healthy China initiative and offering a compelling case study in mission-driven, data‑oriented healthcare delivery

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Intro

• Foundation: 1998 (Ulanqab, Inner Mongolia)
• Headquarters: Beijing, China
• Stock listing: 2010, ChiNext (Shenzhen) - 300049.SZ
• Medical-device subsidiary: Echosens (est. 2001) - developer of FibroScan®
• International footprint: subsidiaries/operations in France, United States, Germany, Spain, United Kingdom, Italy, Singapore, Hong Kong (total presence across 9 jurisdictions)

• Advance early detection and standardized secondary prevention of liver disease to reduce morbidity and mortality from liver cancer.
• Deliver outcome-driven care where payment and clinical pathways are increasingly tied to measurable treatment effectiveness.
• Support national public-health goals - aligning with China's "Healthy China" initiative to widen population screening and improve long-term outcomes.

• Be a global leader in comprehensive liver health management, integrating non-invasive diagnostics, risk-stratified screening, and evidence-based treatment pathways.
• Create scalable models for managing high-risk populations that can be replicated across regions and healthcare systems.

• Patient-first innovation - prioritize technologies and care models that directly improve patient outcomes and quality of life.
• Evidence-based practice - insist on standardized protocols and measurable endpoints to guide screening and secondary prevention.
• Collaboration - partner with hospitals, health authorities, and international research organizations to scale impact.
• Transparency & accountability - link payments and services to demonstrable effectiveness and continuous outcome monitoring.
• Global perspective - combine domestic public-health priorities with international technology and distribution partnerships.

• High-risk population screening: deploy non-invasive tools and structured pathways to identify liver fibrosis and early-stage cancer candidates.
• Standardized secondary prevention: implement evidence-based treatment protocols across partner hospitals and managed-care cohorts.
• Outcome-based payment models: contractually align reimbursement with agreed clinical outcomes and long-term follow-up metrics.
• Device integration: leverage FibroScan® and related non-invasive technologies to scale efficient, ambulatory liver assessments.

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Overview

• Mission emphasis: prevention-first approach targeting the reduction of liver cancer incidence across families and communities.
• Scope: combines diagnostic products, screening programs, clinical collaborations, and public-health campaigns to reach at‑risk populations.
• Geographic priority: strong focus on regions in China with higher hepatitis and liver‑cancer burden, while expanding screening accessibility nationwide.

• Product development: diagnostic assays and screening tools optimized for early detection of liver disease and hepatocellular carcinoma (HCC).
• Clinical partnerships: collaborative screening and prevention programs with county and provincial health authorities and tertiary hospitals.
• Public-health outreach: community screening drives, vaccination and antiviral treatment linkage initiatives aiming to lower progression from chronic liver disease to cancer.

• Scaling screening: targeted community screening programs designed to increase early detection rates in high‑risk cohorts (e.g., HBV-positive individuals aged 40+), with program KPIs such as screening coverage and early-stage detection proportion.
• Linkage to care: pathways to ensure screened-positive individuals receive confirmatory diagnosis and timely antiviral or therapeutic referral, reducing progression risk.
• Partnership metrics: collaboration counts with provincial CDCs, hospitals, and NGOs to broaden public‑health reach.

• The mission has remained a stable strategic north star, informing capital allocation toward diagnostics R&D and community programs rather than broad, unrelated diversification.
• Performance metrics and reporting increasingly reflect public‑health outcomes (screening volumes, detection-stage distributions, linkage-to-care rates) alongside financial KPIs.
• Transparency and stakeholder engagement (regulators, hospitals, patient groups) are used to scale impact while maintaining regulatory compliance and quality standards.

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Mission Statement

• Manufacturing excellence: continuous optimization of production processes to ensure product safety, consistency, and traceability.
• Patient-centered outcomes: prioritizing therapeutic efficacy, accessibility, and post-market surveillance for product safety.
• Regulatory and ethical compliance: strict adherence to GMP, national drug regulatory requirements, and international best practices.
• Stakeholder value: balancing returns for shareholders with responsibilities to employees, patients, and the wider community.

Vision Statement

• Respectful manufacturer - embedding ethics and social responsibility into sourcing, labor practices, and environmental stewardship.
• Leading brand medicine - building recognizable, evidence-backed pharmaceutical brands that set quality benchmarks in their therapeutic niches.
• Service provider in healthcare with industry reputation - expanding beyond products to offer reliable clinical support, training, and patient services that earn professional trust.
• Global influence - scaling presence across domestic and selected overseas markets while respecting local regulatory and cultural contexts.

Core Values Driving the Vision

• Integrity - transparent governance, compliance-first mindset, and accountable reporting.
• Quality - relentless pursuit of product excellence through science-driven processes.
• Respect - for patients, employees, partners, and communities; cultivating a safe and inclusive workplace.
• Innovation - focused R&D to improve therapeutic options and production technologies.
• Service - delivering measurable clinical and logistical support that strengthens healthcare delivery.

Operationalizing the Vision - Key Strategic Levers

• Scaled R&D: concentrate on pipeline prioritization, translational studies, and post-marketing evidence generation to support brand leadership.
• Manufacturing upgrades: invest in automation, real-time quality control systems, and supply-chain resilience.
• Commercial excellence: deepen hospital and distributor relationships, strengthen pharmacovigilance, and expand patient-support services.
• ESG integration: implement measurable environmental targets, enhance workplace safety, and adopt ethical procurement codes.

For an in-depth look at the company's financial dynamics that inform these strategic priorities, see: Breaking Down Inner Mongolia Furui Medical Science Co., Ltd. Financial Health: Key Insights for Investors

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Vision Statement

• Integrity: Upholding transparent governance, regulatory compliance, and ethical conduct across manufacturing, sales, and clinical collaboration.
• Innovation: Sustained investment in R&D to deliver cutting-edge products and platform technologies for diagnostics and minimally invasive treatment.
• Customer focus: Designing solutions around clinician workflows and patient needs to improve satisfaction and clinical outcomes.
• Collaboration: Strategic partnerships with hospitals, research institutes, and distributors to scale impact and market access.
• Responsibility: Commitment to public health, product safety, and environmental stewardship in operations and supply chains.
• Efficiency: Streamlined execution and resource management to translate innovation into affordable, high-quality healthcare solutions.

• R&D acceleration: target to increase R&D spend to ~14% of revenue within 24 months, focusing on next-generation diagnostics and automation.
• Quality and compliance: expand third-party quality audits and maintain full regulatory filings across NMPA and relevant export markets.
• Customer-centric rollout: implement clinician co-development programs and post-market surveillance to increase product adoption and satisfaction.
• Partnership expansion: pursue hospital network collaborations and distribution agreements to grow channel reach by 20% year-over-year.
• Sustainability and responsibility: reduce production waste intensity and institute supplier ethical-audit requirements across top 100 suppliers.